IGHV 突变 CLL 患者骨髓 uMRD 率较低但 36 个月 PFS 率较高参考文献:1. Allan JN, et al. Outcomes in Patients with High-Risk
al. Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax
e1017.3. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk
06-01].6. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk